secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001682852-26-000047
Event type: litigation
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent
--------------------------------------------------------------------------------

- Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.
- Additional $1.3B contingent payment due if Moderna loses appeal on Section 1498 government contractor defense at Federal Circuit.
- Settlement includes fully paid-up, royalty-free license for Moderna's infectious disease vaccines using SM-102 LNP (Spikevax, mNEXSPIKE, mRESVIA, future pipeline).
- Moderna may appeal Section 1498 issue; if partially successful, prorated amount of $1.3B may be due; if fully successful, no further payment.
- Agreement provides mutual releases and dismissals of all pending claims in U.S. and international litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/0001682852-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000047/mrna-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer